Using urinary sugars as a biomarker of consumption, we have previously shown that obese people consume significantly more sugars than individuals of normal weight. However, there is concern that recovery of this biomarker may differ between normal weight and obese individuals. A total of 19 subjects, divided into two groups according to their body mass index (BMI) (normal weight BMIp25 kg/m 2 , n ¼ 10; obese BMIX30 kg/m 2 , n ¼ 9), participated in a randomized crossover dietary intervention study of three diets providing 13, 30 and 50% of energy from sugars for 4 days each while living in a volunteer suite. The mean urinary sucrose and fructose excretions in 24-h urine increased with increasing sugar consumption over the three dietary periods in both BMI groups and were significantly different between the diets (Po0.01). There was no significant interaction effect of BMI class on the mean urinary excretions of these sugars with different sugar intakes, either as absolute values or expressed as a percentage of total sugar intake. In conclusion, BMI does not affect the validity of sucrose and fructose excretions in 24-h urine collections used as biomarkers to estimate total sugar consumption.
Introduction
Using a newly developed urinary biomarker of sugar intake, 1 but not from self-reported food intake, we have shown recently that obese individuals consumed more sucrose than normal weight individuals. 2 Urinary sucrose and fructose can be used as biomarkers because sucrose found in urine originates from dietary sucrose that escapes hydrolysis by sucrase in the small intestine and is subsequently removed from the circulation by excretion in the urine. 3 Urinary fructose originates from dietary fructose and hydrolyzed sucrose that escapes fructose hepatic metabolism. However, disturbances in small intestinal motility, 4 though not confirmed in other studies, 5 and an elevated rate of nutrient uptake in the proximal intestine 5 have been reported in obesity. Genetically obese mice show increased intestinal permeability, 6 sucrase activity 7 and absorptive capacity 8 compared with their lean littermates. These factors introduce concern that the use of urinary sugars as biomarkers of intake in obese individuals may not be valid due to the fact that absorption and hence excretion is increased. We have therefore compared the urinary recovery of sugars in obese and normal weight individuals.
Materials and methods

Subjects
Participants had to be healthy, between 20 and 85 years of age, free from diabetes and bowel disease, not taking medication affecting the gut for at least 3 months before the study and not pregnant. Exclusion criteria included participation in another biochemical intervention study at the same time and glucose in urine as shown by reagent strips for urinalysis (Bayer Diagnostics Mfg Ltd, Bridgend, UK). Before the study, subjects were examined by a medical practitioner. Two subjects were smokers. Two subjects in the obese group were treated for hypertension with diuretics and angiotensin converting enzyme inhibitors. One of them was additionally treated for high cholesterol with statins and regularly took a non-steroidal anti-inflammatory drug. In the normal weight group, one volunteer was on thyroxin and had normal thyroid hormone levels. ). Subjects received verbal and written information and signed a written consent form. The study was approved by the Cambridge Local Research Ethics Committee. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research.
Study design
The study was a randomized crossover dietary intervention study of three 4-day dietary periods of low-(LS), medium-(MS) and high-sugar (HS) intake, with sugars contributing 13, 30 and 50% to energy intake, respectively. The HS diet was particularly high and the LS particularly low in refined sugars. Diets contained a constant proportion of energy as protein (12%) and starch (23%). Fat intake decreased with increasing sugar content, contributing 52% to energy intake in the LS diet, 34% in the MS diet and 15% in the HS diet.
Energy intake was matched to estimated energy requirement 9 by adding 1 MJ LS, MS or HS increments to standard 10 MJ diets (Appendix). On days 3 and 4 of each dietary period, subjects collected 24-h urine. Completeness of urine collections was assessed by urinary recovery of three 80 mg tablets of p-amino benzoic acid (PABA; PABAcheck, MRC Dunn Human Nutrition Unit, UK). 10 Subjects lived in the volunteer suite of the MRC Dunn Human Nutrition Unit during the study.
Urine analysis
Urine collection bottles contained boric acid as preservative, which was shown previously not to affect the stability of sucrose. 1 PABA recovery was measured as described before.
11
High PABA recoveries (4110%) were repeated by highperformance liquid chromatography analysis 12 to exclude possible drug interference. Urine samples were thawed only once before analysis to prevent recurrent freeze-thaw degeneration of sucrose. To improve specificity and reduce analytical costs, urinary sucrose was analyzed using liquid chromatography with mass spectrometric detection as described previously. 13 Urinary fructose could not be analyzed with this technique as the peaks for fructose and glucose overlay and was therefore analyzed using an enzymatic method (sucrose/ D-glucose/D-fructose kit; Boehringer Mannheim, Mannheim, Germany/R-Biopharm Rhône Ltd, Glasgow, UK). Power was calculated using data from a previous study, 1 in which s was 10 mg. A mean difference of 12.5 mg in urinary sucrose excretion, equivalent to an intake of total sugars of B75 g, would be detected for 10 subjects in each group. Seventy-five grams sufficiently discriminate between habitual LS, MS and HS consumption and therefore would classify both groups of normal weight and obese volunteers in the same total sugar intake level.
Statistical analysis
Results
Extra increments were required in the obese group as expected from higher energy requirements associated with maintaining an increased body weight. Energy intake was 11.4±0.5 MJ d
À1
in obese and 10.4 ± 0.2 MJ d À1 in normal weight subjects, resulting in significantly higher absolute intakes of total sugars on the LS and HS diets in the obese group (Table 1) . Of 114 24-h urine collections, six collections were incomplete and were excluded from the analyses. Fourteen collections were marginally incomplete (PABA recovery 70-85% on day 3 or 70-90% on day 4) and urinary sucrose and fructose values corrected to an average PABA recovery of 93%;
14 results from analysis of variance using uncorrected sucrose values were similar. Mean PABA recovery was lower in the normal weight (93.5 ± 1.4%) than in the obese group (99.6 ± 1.8%; P ¼ 0.02). The mean urinary sucrose and fructose excretions on days 3 and 4 of each dietary period were used, unless one of the two days was incomplete. Both the mean urinary sucrose and fructose excretion increased with increasing sugar consumption over the three dietary periods in both BMI groups ( Figure 1 . 
Discussion
Urine concentrations rapidly responded to changes in the diet (Figure 1 ) as shown before, 1, 15 indicating that urinary sucrose and fructose excretions are sensitive to dietary intake. Despite the large interindividual variation in absolute urinary concentrations and the degree of change in response to diet, the variation is similar in normal weight and obese subjects ( Figure 1 ). There was no significant interaction with BMI class in the dose-response relations, which indicates that sucrose and fructose excretions in 24-h urine collections can be used to assess dietary intake and estimate disease risk related to sugar consumption in both normal weight and obese subjects. The use of this biomarker to assess sugar consumption in a representative UK population is being investigated in this laboratory.
The day-to-day variation in habitual sugar intake is high, but as between-subject variation is higher than withinsubject variation, 1, 16 classification of individuals as either low or high sugar consumers is relatively precise within populations. 17 Accordingly, this study was powered to classify both groups of normal weight and obese volunteers and obese ( * , dotted line) subjects.
Urinary biomarkers of sugar consumption AMCP Joosen et al in the same total sugar intake level with LS, MS and HS consumption. We should note, however, that although we recruited apparently healthy volunteers, some subjects were taking medication. With the exception of non-steroidal antiinflammatory drugs, which are associated with increased gastrointestinal permeability, 18 to our knowledge disturbances in gastrointestinal permeability have not been reported for any of the other medications. Addition of antihypertensive medication (n ¼ 2) and use of non-steroidal anti-inflammatory drug (n ¼ 1) as covariates in the repeated measures analysis of variance did not change the results, but drug or disease interactions should be considered in certain populations as increased urinary disaccharide excretion is associated with several gastrointestinal disorders, such as Crohn's and gastric disease. 19, 20 We conclude that BMI does not affect the validity of sucrose and fructose excretions in 24-h urine collections used as biomarkers to estimate total sugar consumption. Urinary biomarkers of sugar consumption AMCP Joosen et al
